文献速递药物相互作用

匹莫迪韦单次和多次给药药代动力学及与奥司他韦相互作用

Single- and multiple-dose pharmacokinetics and safety of pimodivir, a novel, non-nucleoside polymerase basic protein 2 subunit inhibitor of the influenza A virus polymerase complex, and interaction with oseltamivir: a Phase 1 open-label study in healthy volunteers.
PubMed 文献 · Br J Clin Pharmacol · 2018-09-14

本研究为开放标签1期试验,在健康志愿者中评估匹莫迪韦与奥司他韦联用的药物相互作用,并考察匹莫迪韦单次和多次给药的药代动力学与安全性。结果显示联用使匹莫迪韦Cmax升高31%,但对奥司他韦及其羧基代谢物药代动力学无影响,未发现临床相关药物相互作用或安全性问题。

要点

  • 匹莫迪韦与奥司他韦联用无临床相关药物相互作用。
  • 联用使匹莫迪韦Cmax升高31%,Cmin和AUC12h无变化。
  • 匹莫迪韦600mg每日两次单用或联用奥司他韦75mg每日两次未发现安全性问题。

核心结论

  • 健康志愿者中匹莫迪韦与奥司他韦联用未显示临床相关药物相互作用。
  • 匹莫迪韦600mg每日两次单用或联用奥司他韦75mg每日两次未发现安全性问题。

研究设计与样本

  • 开放标签1期研究,分两部分。
  • Part 1纳入健康志愿者18例,随机交叉设计,比较奥司他韦75mg、匹莫迪韦600mg及两者联用每日两次给药。
  • Part 2纳入健康志愿者16例,随机接受匹莫迪韦600mg或安慰剂(3:1)每日两次给药。

主要发现

  • Part 1中联用奥司他韦使匹莫迪韦Cmax升高31%(90%CI:0.92-1.85),Cmin和AUC12h无变化。
  • 匹莫迪韦对奥司他韦或奥司他韦羧基代谢物药代动力学无影响。
  • Part 2中匹莫迪韦单次和多次给药后,第1天至第10天Cmax和AUC12h分别增加1.2倍和1.8倍。
  • 最常见治疗中出现的不良事件为腹泻(Part 1和Part 2各7例)。

临床怎么用

  • 匹莫迪韦与奥司他韦联用无需基于药代动力学相互作用调整剂量。
  • 临床使用匹莫迪韦600mg每日两次时需关注腹泻等不良事件。

局限性

  • 研究为开放标签设计,样本量有限。
  • 研究对象为健康志愿者,未纳入流感患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The aim of this study was to evaluate the drug-drug interaction between pimodivir, a novel, non-nucleoside polymerase basic protein 2 (PB2) subunit inhibitor of the influenza A virus polymerase complex, and oseltamivir, to assess the feasibility of this combination therapy. Furthermore, single- and multiple-dose pharmacokinetics and safety of pimodivir in healthy volunteers were assessed. METHODS: In Part 1 of this open-label Phase 1 study, healthy volunteers (n = 18) were randomized to one of six cross-over treatment sequences, each comprising administration of oseltamivir 75 mg or pimodivir 600 mg or combination thereof twice daily on Days 1-4, followed by a single morning dose on Day 5. Between each treatment session, there was a minimum 5-day washout period. In Part 2, healthy volunteers (n = 16) randomly received pimodivir 600 mg or placebo (3:1) twice daily on Days 1-9, followed by a single morning dose on Day 10. Pharmacokinetics of pimodivir, oseltamivir and oseltamivir carboxylate, and safety were assessed. RESULTS: In Part 1, co-administration of pimodivir with oseltamivir increased the Cmax of pimodivir by 31% (90% CI: 0.92-1.85) with no change in Cmin or AUC12h . Pimodivir had no effect on oseltamivir or oseltamivir carboxylate pharmacokinetics. In Part 2, after single- and multiple-dose administration of pimodivir, there was a 1.2- and 1.8-fold increase in Cmax and AUC12h , respectively, between Day 1 and Day 10. The most frequently reported treatment-emergent adverse event was diarrhoea (n = 7 each in Part 1 and 2). CONCLUSION: Combination treatment with pimodivir and oseltamivir in healthy volunteers showed no clinically relevant drug-drug interactions. No safety concerns were identified with pimodivir 600 mg twice daily alone or in combination with oseltamivir 75 mg twice daily.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Deleu S, Kakuda TN, Spittaels K, et al. Single- and multiple-dose pharmacokinetics and safety of pimodivir, a novel, non-nucleoside polymerase basic protein 2 subunit inhibitor of the influenza A virus polymerase complex, and interaction with oseltamivir: a Phase 1 open-label study in healthy volunteers. Br J Clin Pharmacol. 2018. PMID: 30098042. doi:10.1111/bcp.13733

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。